Rain Competitors

Delisted . USA . 
Stock . Rain Therapeutics
RAINDelisted Stock  USD 1.41  0.01  0.70%   
Rain Therapeutics competes with Ocean Biomedical, Enveric Biosciences, Elevation Oncology, Hepion Pharmaceuticals, and Zura Bio; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Rain Therapeutics competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Rain Therapeutics to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Rain Therapeutics competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
1.411.411.41
Details
Intrinsic
Valuation
LowRealHigh
1.341.341.55
Details
Naive
Forecast
LowNextHigh
2.362.362.36
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.221.351.48
Details

Rain Therapeutics Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Rain Therapeutics and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Rain and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Rain Therapeutics does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
ZURA
+ 0.83
ENVB
ENVB
+ 0.81
OCEA
ZURA
+ 0.77
OCEA
ELEV
+ 0.43
AVRO
EFTR
+ 0.37
OCEA
CWBR
+ 0.36
AVRO
  
High negative correlations   
OCEA
- 0.91
AVRO
ENVB
- 0.84
AVRO
ZURA
- 0.83
AVRO
OCEA
- 0.46
CWBR
ELEV
- 0.43
OCEA
ZURA
- 0.32
ELEV

Risk-Adjusted Indicators

There is a big difference between Rain Stock performing well and Rain Therapeutics Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Rain Therapeutics' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
All Fundamental Data

Rain Therapeutics Competitive Analysis

The better you understand Rain Therapeutics competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Rain Therapeutics' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Rain Therapeutics' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
RAIN AVRO CWBR OCEA ENVB ELEV HEPA ZURA EFTR
 0.70 
 1.41 
Rain
 2.78 
 1.40 
AVROBIO
 2.29 
 2.99 
CohBar
 4.62 
 0.68 
Ocean
 9.09 
 0.36 
Enveric
 4.48 
 0.64 
Elevation
 4.84 
 0.59 
Hepion
 3.64 
 2.28 
Zura
 30.00 
 0.13 
Effector
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Relatively risky
Very risky
Dangerous
Relatively risky
Relatively risky
Very steady
Market Performance
(90 Days Performance)
Very Weak
Very Weak
Very Weak
Very Weak
Very Weak
Insignificant
Very Weak
Very Weak
Very Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
Dangerous
Dangerous
Dangerous
Very High
Very High
Very High
Very High
Below Average
Dangerous
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Sell
Buy
Strong Buy
Hold
Strong Buy
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Not Rated
Not Rated
Not Rated
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Current Ratio
7.2
11.11
28.45
N/A
8.33
6.48
8.77
N/A
1.79
Net Asset
135.18 M
101.09 M
16.37 M
5.5 M
4.3 M
89.09 M
18.09 M
100.84 M
20.54 M
EBITDA
(73.56 M)
(71.05 M)
(12.07 M)
(957.74 K)
(17.14 M)
(41.47 M)
(49.26 M)
(60.56 M)
(33.73 M)
Current Valuation
(32.85 M)
(26.51 M)
(23.26 M)
35.65 M
(3.46 M)
(34.44 M)
6.53 M
149.21 M
(4.52 M)
Price To Book
0.65
0.6
0.28
100.67
0.91
0.54
2.11
0.97
13.38
Retained Earnings
(165.69 M)
(477.27 M)
(96.91 M)
(196.06 M)
(96.5 M)
(195.97 M)
(224.63 M)
(103.49 M)
(179.38 M)
Current Asset
N/A
30.6 M
8.17 M
N/A
N/A
N/A
4.82 M
N/A
N/A
Beta
0.27
1.22
1.89
1.53
0.47
1.25
1.81
0.14
0.83
Number Of Employees
63
13
9
N/A
7
29
22
14
14
Shares Outstanding
27.58 M
44.89 M
2.91 M
34.65 M
9.94 M
59.12 M
6.96 M
63.77 M
4.7 M
Cash Flow From Operations
(65.76 M)
(63.19 M)
(10.45 M)
(9.43 M)
(14.09 M)
(56.18 M)
(40.89 M)
(15.05 M)
(29.55 M)
Total Debt
277 K
878 K
366.28 K
12.12 M
2.34 M
30.14 M
209.02 K
21.29 M
19.45 M
Return On Equity
-0.97
0.43
-0.84
N/A
-2.06
-0.64
-1.9
-0.37
-9.47
Z Score
92.82
N/A
-5.99
N/A
N/A
N/A
N/A
N/A
N/A
Return On Asset
-0.52
-0.35
-0.48
-6.82
-0.8
-0.25
-0.93
-0.21
-0.83
Number Of Shares Shorted
661.11 K
139.56 K
14.57 K
161.41 K
115.51 K
6.13 M
47.19 K
5.16 M
91.62 K
Book Value Per Share
1.86
1.98
3.27
-2.21
0.71
1.17
1.16
2.34
0.21
Current Liabilities
N/A
3.26 M
1.01 M
N/A
N/A
N/A
1.81 M
N/A
N/A
Total Asset
135.18 M
101.09 M
16.37 M
5.5 M
4.3 M
89.09 M
18.09 M
100.84 M
20.54 M
Debt To Equity
0.003
0.13
0.014
N/A
0.005
N/A
0.001
N/A
1.03
Short Ratio
1.9
0.7
0.28
2.64
0.31
9.52
0.92
5.43
0.97
Target Price
1.58
2.0
18.0
18.5
8.32
7.0
30.0
15.0
11.0
Shares Owned By Institutions
68.38
68.8
2.6
11.62
7.05
83.89
7.85
53.29
23.71
Market Capitalization
44.01 M
63.75 M
2.21 M
25.64 M
3.61 M
37.61 M
4.11 M
295.78 M
846.79 K
Price To Earning
N/A
-4.11
-31.16
N/A
N/A
0.16
-3.01
N/A
1.03
Price To Sales
N/A
N/A
N/A
N/A
0.0831
N/A
N/A
N/A
69.65
Net Income
(72.26 M)
12.16 M
(12.18 M)
(114.47 M)
(17.29 M)
(45.7 M)
(48.93 M)
(60.56 M)
(35.81 M)
Earnings Per Share
-2.07
0.69
-4.37
-3.0
-2.42
-0.8
-4.4
0.57
-12.57
Shares Owned By Insiders
16.48
1.65
15.09
71.98
6.92
0.24
0.085
31.87
2.9
Working Capital
111.66 M
93.91 M
15.18 M
(3 M)
1.24 M
83.82 M
12.2 M
80.54 M
(5.96 M)
Cash And Equivalents
90.73 M
132.41 M
20.1 M
N/A
18.01 M
122.54 M
59.15 M
N/A
41.04 M
Cash Per Share
3.41
3.03
6.92
N/A
11.44
5.26
0.78
N/A
0.99
Gross Profit
N/A
N/A
N/A
N/A
8.15 M
N/A
N/A
N/A
(19.76 M)
Day Typical Price
1.4
1.41
3.01
0.67
0.36
0.64
0.6
2.25
0.12
Accumulation Distribution
0.0423
0.0417
0.0261
0.0441
0.0541
0.1
0.0952
0.0733
0.59
Market Facilitation Index
0.06
0.06
0.08
0.03
0.02
0.07
0.06
0.17
0.1
Daily Balance Of Power
(0.17)
(0.67)
(0.88)
1.0
1.5
(0.43)
(0.50)
0.4706
0.3
Period Momentum Indicator
(0.01)
(0.04)
(0.07)
0.03
0.03
(0.03)
(0.03)
0.08
0.03
Rate Of Daily Change
0.99
0.97
0.98
1.05
1.09
0.96
0.95
1.04
1.3
Day Median Price
1.39
1.41
3.02
0.67
0.36
0.65
0.6
2.24
0.12
Price Action Indicator
0.015
(0.03)
(0.07)
0.03
0.015
(0.02)
(0.03)
0.085
0.025
Relative Strength Index
22.1
67.88
53.16
34.29
21.39
54.2
53.24
33.43
29.74
Coefficient Of Variation
(1,877)
1615.56
1137.53
(1,080)
(1,264)
2569.58
(2,737)
(971.03)
(333.16)
Mean Deviation
4.26
1.77
7.34
3.15
3.29
3.78
3.61
4.11
7.57
Jensen Alpha
(0.83)
0.0699
2.07
(0.39)
(0.38)
0.0397
(0.29)
(0.78)
(4.62)
Total Risk Alpha
(2.05)
(0.17)
(1.03)
(0.95)
(1.00)
(0.44)
(0.86)
(1.22)
(6.45)
Sortino Ratio
N/A
0.0229
0.3314
N/A
N/A
0.0175
N/A
N/A
N/A
Downside Variance
N/A
5.54
51.11
N/A
N/A
28.81
N/A
N/A
N/A
Standard Deviation
11.49
2.49
28.09
4.33
4.86
4.98
5.27
5.31
15.18
Kurtosis
52.59
3.23
61.27
5.5
4.69
0.6889
7.19
1.09
17.04
Potential Upside
4.89
4.11
5.73
4.62
8.0
8.33
8.06
7.95
8.7
Treynor Ratio
(0.27)
0.1751
0.5686
1.51
1.99
0.1149
(0.20)
(0.23)
(7.83)
Maximum Drawdown
98.38
14.2
250.97
27.01
28.33
22.33
33.54
26.7
88.91
Variance
132.09
6.19
788.94
18.71
23.61
24.82
27.72
28.18
230.42
Market Risk Adjusted Performance
(0.26)
0.1851
0.5786
1.52
2.0
0.1249
(0.19)
(0.22)
(7.82)
Risk Adjusted Performance
(0.03)
0.052
0.0735
(0.06)
(0.05)
0.0368
(0.02)
(0.07)
(0.21)
Skewness
(6.86)
1.15
7.67
1.58
1.51
0.3316
1.82
(0.57)
(3.83)
Semi Deviation
N/A
1.89
5.34
N/A
N/A
4.58
N/A
N/A
N/A
Information Ratio
(0.06)
0.0217
0.0843
(0.12)
(0.1)
0.0188
(0.06)
(0.12)
(0.31)
Value At Risk
(6.14)
(3.17)
(5.59)
(6.06)
(7.50)
(8.06)
(8.00)
(9.71)
(27.78)
Expected Short fall
N/A
(2.24)
(11.19)
N/A
N/A
(4.22)
N/A
N/A
N/A
Downside Deviation
N/A
2.35
7.15
N/A
N/A
5.37
N/A
N/A
N/A
Semi Variance
N/A
3.58
28.49
N/A
N/A
20.98
N/A
N/A
N/A

Rain Therapeutics Competition Performance Charts

Five steps to successful analysis of Rain Therapeutics Competition

Rain Therapeutics' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Rain Therapeutics in relation to its competition. Rain Therapeutics' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Rain Therapeutics in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Rain Therapeutics' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Rain Therapeutics, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Rain Therapeutics position

In addition to having Rain Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Climate Change Thematic Idea Now

Climate Change
Climate Change Theme
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.

Other Consideration for investing in Rain Stock

If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY